Canada markets open in 4 hours 37 minutes
  • S&P/TSX

    18,979.01
    -256.08 (-1.33%)
     
  • S&P 500

    3,744.52
    -38.76 (-1.02%)
     
  • DOW

    29,926.94
    -346.93 (-1.15%)
     
  • CAD/USD

    0.7287
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    88.92
    +0.47 (+0.53%)
     
  • BTC-CAD

    27,417.96
    -385.25 (-1.39%)
     
  • CMC Crypto 200

    454.82
    -8.30 (-1.79%)
     
  • GOLD FUTURES

    1,720.10
    -0.70 (-0.04%)
     
  • RUSSELL 2000

    1,752.51
    -10.18 (-0.58%)
     
  • 10-Yr Bond

    3.8260
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,491.00
    -50.75 (-0.44%)
     
  • VOLATILITY

    30.50
    +1.95 (+6.83%)
     
  • FTSE

    6,983.25
    -14.02 (-0.20%)
     
  • NIKKEI 225

    27,116.11
    -195.19 (-0.71%)
     
  • CAD/EUR

    0.7427
    +0.0001 (+0.01%)
     

What You Need To Know About NeuroOne Medical Technologies Corporation's (NASDAQ:NMTC) Investor Composition

·4 min read

Every investor in NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

NeuroOne Medical Technologies is not a large company by global standards. It has a market capitalization of US$31m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about NeuroOne Medical Technologies.

View our latest analysis for NeuroOne Medical Technologies

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About NeuroOne Medical Technologies?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that NeuroOne Medical Technologies does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of NeuroOne Medical Technologies, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 18% of NeuroOne Medical Technologies. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that Manchester Management Company, LLC is the largest shareholder with 9.3% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 8.7% and 3.1%, of the shares outstanding, respectively. Additionally, the company's CEO David Rosa directly holds 1.6% of the total shares outstanding.

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of NeuroOne Medical Technologies

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in NeuroOne Medical Technologies Corporation. It has a market capitalization of just US$31m, and insiders have US$2.2m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, mostly comprising of individual investors, collectively holds 62% of NeuroOne Medical Technologies shares. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - NeuroOne Medical Technologies has 7 warning signs (and 3 which are a bit concerning) we think you should know about.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.